Introduction
============

Bisphenol A (BPA) is an industrial chemical used in the manufacture of polycarbonate plastic found in a number of consumer products such as thermal paper, canned foods and epoxy resins ([@B33]) -- although many of these uses are being phased out ([@B46]). Amongst the general population, exposure to BPA is widespread, with very low levels of BPA present in the majority of urinary samples taken in the general population ([@B5]), although serum levels are estimated to be lower ([@B39]). Release of BPA to the environment exceeds one million pounds per year ([@B33]).

Bisphenol-A has been subjected to a high-level of scrutiny -- "bisphenol A" returns over 11,500 abstracts in PubMed, with over 700 articles per year being published every year since 2013 ("[@B31], [@B31]). Within HSDB (the Hazardous Substance Database), there are over 79 peer-reviewed animal studies ([@B40], [@B40]). The CLARITY study, a three generation chronic study with low-levels of BPA used to mimic population exposures, involved 3,500 rats: while it resulted in no revision of safety standards by the FDA, it still failed to bring about a consensus as to a safe level ([@B1], [@B1]). Despite the overwhelming amount of data, the mechanism(s) by which BPA may exert adverse effects remains unclear, nor is there a widely agreed upon endpoint on which to base a safe dose.

Bisphenol-A was presumed to have potentially estrogenic activity, as well as potential carcinogenicity, based on its structural similarity to DES (Diethylstilbestrol) and other synthetic estrogens, as well as appearing to trigger gene expression similar to estrogen receptor agonists, despite its relatively low binding affinity for estrogen receptors ([@B22]). Two different hypotheses have been put forward to explain this discrepancy: one, BPA may bind to different domains of ESR1 or ESR2 and recruit different co-regulators ([@B34]), or alternatively, BPA may exert its effects through non-classical estrogen receptors, such as membrane-bound ER (GPR30) ([@B22]) or ERRγ (ERRG) ([@B27]), which is one of several "orphan" receptors that are classified as estrogen-related receptors ([@B14]). The question of BPA's ultimate molecular initiating event is not academic -- on the presumption that BPA's effects are mediated via estrogen receptors, several alternatives were proposed, such as Bisphenol F and Bisphenol S, but both compounds have proven equally problematic ([@B32]).

In our previous work for the Mapping the Human Toxome project ([@B15]; [@B4]), we demonstrated that using non-inferential statistical methods that did not depend on existing annotations such as IDEA ([@B29]) and WGCNA ([@B25]) offered a powerful method to untangle possible regulatory mechanisms and providing insight into possible Pathways of Toxicity compared to either inferential-based methods or approaches such as pathway enrichment analysis that depend exclusively on annotations. Building upon our previous work using WGCNA applied to *in vitro* transcriptomic data to more fully understand the transcription factors that are driving the biology of estradiol ([@B29]), we used WGCNA to examine a previously published transcriptomic dataset ([@B36]). Briefly, [@B36] aimed to study the sensitivities of estrogen responsive genes to various endocrine disrupting chemicals (EDCs) based on the transcriptomic profile of MCF-7 cells exposed to either estrogen or several xenoestrogens (including BPA) over a dose-response curve ranging from picomolar to micromolar concentrations for a 48 h time period. Based on their analysis, they found that a gene signature of "estrogen-responsive genes" allowed the estrogenic substances to be ranked in terms of potency. Additionally, the heat map of BPA-inducible genes demonstrated a weak transcriptional activation at very low BPA concentration as well as a strong peak at high concentration. However, BPA has differences as well as similarities to estrogen in terms of gene signatures: therefore, we sought to explore specifically the differences between estrogen and BPA as well as the differences between low-dose BPA and high-dose BPA for possible regulatory mechanisms.

Our analysis shows that while there is substantial overlap between genes altered by BPA and estrogen, which might imply that BPA is indeed "estrogenic," there are important differences in network topology as well as biological function, and that the overlap appears to be driven by transcription factors such as ZNF217, TFAP2C, PADI4, and RACK7/ZMYND8 rather than the estrogen receptor *per se*. Furthermore, BPA (even at the lower end of the dose response curve - defined here as less than 12.5 μM) has pathways that are likely not mediated by estrogen receptors, but instead by other transcription factors, such as SREBF1. Moreover, our data is consistent with other reports that BPA leads to subtle, diffuse gene changes that are comparatively difficult to capture with inferential methods, and that low-dose BPA has distinct effects compared to higher doses.

Materials and Methods {#s1}
=====================

Data
----

Dataset GSE50705, a comprehensive analysis of estrogen and xenoestrogen dose-response curves on MCF-7 cells after 48 h of exposure, was downloaded from GEO via GEOQuery ([@B8]) as normalized data and all analyses were performed with R/Bioconductor ([@B12]).

Weighted Gene Correlation Network Analysis
------------------------------------------

A WGCNA network ([@B20]) was generated for several subsets of the data: Estrogen (*n* = 36), BPA (*n* = 44), and low dose BPA (*n* = 32), as well as a consensus network for estrogen and BPA together (*n* = 80) using the 10,000 most highly expressed genes for each subset of the data as determined by rank means expression, the approach in [@B25]; consensus networks and module statistics followed overall the approach in [@B21]. Briefly, the network was derived based on a signed Spearman correlation using a β of 10 as a weight function. The topological overlap metric (TOM) ([@B44]) was derived from the resulting adjacency matrix, and was used to cluster the modules using the blockwiseModules function (blockwiseConsensusModules, for the consensus modules) and the dynamic tree cut algorithm ([@B21]) with a height of 0.25 and a deep split level of 2, a reassign threshold of 0.2 and a minimum module size of 30 (100 for the consensus network). The eigenmodules--- essentially the first principal component of the modules, which can be used as a "signature" of the modules gene expression ---were then correlated with dose, and each module that was correlated with the dose-response curve with a *p*-value \< 0.01 (*p*-value \< 0.05 for the consensus network) was considered statistically significant.

Transcription Factor Analysis
-----------------------------

All statistically significant modules were analyzed in EnrichR ([@B6]) using the CHEA dataset ([@B19]) restricted to MCF-7/10 cells --as well as the ARCHS4 TF-Coexpression dataset with an adjusted *p*-value less than 0.01 based on Fisher's exact test.

Functional Annotation Analysis
------------------------------

Module "hubs" were defined as having high-ranking kME (which ranks the connectivity of genes) within the module and predicted as high-degree within the STRING database ([@B38]) of protein--protein interactions. The three highest ranking modules were analyzed in STRING for the enrichment of predicted protein interactions as well as functional annotation via GO Biological Process and Molecular Function. All analysis with STRING was done with medium stringency settings, and included all possible interactions (text-mining, database, experiments, co-expression, neighborhood, gene fusion, and co-occurrence).

TCGA Data
---------

Expression and methylation data for FIZ1 was correlated with clinical attributes (estrogen receptor, progesterone receptor, and solid tumor vs. normal vs. metastatic tumor) using MEExpress ([@B17]) based on the TCGA BRCA dataset.

Results
=======

Consensus Network Analysis Indicates Minimal Overlap Between Estrogen and BPA
-----------------------------------------------------------------------------

We began by analyzing the dose-response curve of the BPA and estrogen dataset combined using WGCNA (which takes advantage of correlations amongst genes and groups genes into modules using network topology) to look for a "consensus network"-a common pattern of genes that are correlated in all conditions. The consensus network identified (Figure [1](#F1){ref-type="fig"}) had clearly delineated modules, and the modules identified were significantly correlated with both estrogen (Figure [2](#F2){ref-type="fig"}) and BPA (Figure [3](#F3){ref-type="fig"}). However, estrogen clearly had a stronger signal in comparison to BPA and quite possibly overwhelmed the signal from BPA. More strikingly, however, the majority of modules in the consensus analysis when analyzed for correlation with both BPA and estrogen showed virtually no similarity -- most modules had opposite directions of correlation, and of the few modules with similar correlations, the coefficient of correlation was very weak -- only one module ("yellow") was significant with a *p*-value \< 0.05 (Table [1](#T1){ref-type="table"}), indicating that while there may be some overlap in genetic signatures, from a network topology perspective there is minimal conservation. When analyzed for transcription factors against the CHEA dataset -- a collection of ChIP-chip, ChIP-seq, ChIP-PET, and DamID studies collected into a database to infer transcriptional regulation ([@B19]) -- the common module was enriched for E2F1, ZNF217, and RACK7, but not ESR1 or ESR2 (Table [2](#T2){ref-type="table"}).

![Consensus network from BPA and Estrogen dose-response curve. Gene expression similarity is determined using a pair-wise weighted correlation metric, and clustered according to a topological overlap metric into modules; assigned modules are colored on bottom, gray genes are unassigned to a module.](fgene-09-00508-g001){#F1}

![Consensus network modules correlated with estrogen dose using the eigenmodule (the first principal component of the module). Correlation coefficient along with *p*-value in parenthesis underneath; color-coded according to correlation coefficient (legend at right).](fgene-09-00508-g002){#F2}

![Consensus network modules correlated with BPA dose using the eigenmodule (the first principal component of the module). Correlation coefficient along with *p*-value in parenthesis underneath; color-coded according to correlation coefficient (legend at right).](fgene-09-00508-g003){#F3}

###### 

Consensus network modules associated with BPA and estrogen.

  Module    Correlation   *p*-value
  --------- ------------- -----------
  Red       -0.00025      1
  Green     -0.092        0.4
  Purple    NA            NA
  Black     NA            NA
  Brown     NA            NA
  Magenta   NA            NA
  Blue      NA            NA
  Yellow    0.24          0.03
  Pink      0.18          0.1
  Gray      NA            NA

Consensus network modules were correlated against both estrogen and BPA; NA indicates that the modules had different directions of correlation in estrogen compared to BPA.

###### 

Enriched transcription factors in conserved module in consensus network.

  Transcription factor   Adjusted *p*-value
  ---------------------- --------------------
  E2F1                   0.000003501
  ZNF217                 0.000004066
  RACK7/ZMYNDB           0.005142

Transcription factors significantly enriched in the conserved module ("yellow") between BPA and estrogen.

Estrogen and BPA Network Overlap With Transcription Factors, Including ESR1 and ESR2, but With Different Network Topologies and Different Biological Processes
--------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we derived the *de novo* networks individually for the entire dose-response curve of estrogen and BPA to examine the network topology, common hubs, and biological role of the modules in each network separately. Within the estrogen network (Supplementary Figure [1A](#SM1){ref-type="supplementary-material"}), there was one large module highly correlated with estrogen dose ("turquoise") (Table [3](#T3){ref-type="table"}), which was also enriched for ESR1 and ESR2 in addition to E2F1, ZNF217, TFAP2C amongst others (Table [4](#T4){ref-type="table"}); furthermore, ESR1 was a hub within the module, and the module was predominately enriched with terms related to cell-cycle as well as poly(A) RNA binding (Supplementary Table [1](#SM3){ref-type="supplementary-material"}).

###### 

Estrogen modules correlated with dose.

  Module          Correlation   *p*-value
  --------------- ------------- -----------
  Turquoise       0.710543783   1.73E-06
  Dark Green      0.667630497   1.18E-05
  Dark Red        0.548734271   6.42E-04
  Light Yellow    0.470241047   4.36E-03
  Brown           0.45994764    5.44E-03
  Salmon          0.443256223   7.66E-03
  Gray60          -0.47528565   3.91E-03
  Blue            -0.5389571    8.36E-04
  Yellow          -0.55352085   5.62E-04
  Black           -0.63950993   3.54E-05
  Midnight Blue   -0.73602275   4.69E-07

All modules correlated with estrogen dose-response curve with a p-value less than 0.01.

###### 

Enriched transcription factors in estrogen modules.

  Module      TF       Adjusted *p*-value
  ----------- -------- --------------------
  Black       RACK7    0.005152
  Blue        ZNF217   2.79E-14
              PADI4    1.10E-08
              RACK7    8.23E-07
              TFAP2C   0.00001662
              GATA3    0.00004515
              FOXM1    0.000373
              E2F1     0.000674
  Turquoise   E2F1     1.43E-20
              ESR1     7.21E-10
              ESR2     2.12E-09
              PADI4    1.34E-07
              RACK7    7.39E-07
              GATA3    0.0000105
              RUNX1    0.0003015
              ZNF217   0.0006679
              TFAP2C   0.0008849
              ELK1     0.001171
              FOXM1    0.001239
  Yellow      PADI4    0.001012
              RUNX1    0.001601

All statistically significant modules correlated with dose, with enriched transcription factors. Modules that did not have TFs with an adjusted p-value ≤ 0.01 were excluded (Dark Red, Dark Green, Salmon, Midnight Blue, Gray60).

In comparison, the top module correlated with BPA dose ("lightcyan1") (Supplementary Figure [1B](#SM1){ref-type="supplementary-material"}) (Table [5](#T5){ref-type="table"}), was a relatively small module not enriched for any transcription factors, however, SSR1 (Signal Sequence Receptor Subunit 1) was the top hub; annotation analysis revealed that the module was enriched for genes in the GO category of "response to endoplasmic reticulum stress" and "endoplasmic reticulum unfolded protein response" (*p*-value of 2.93E-17 and 2.02E-12, respectively) (Supplementary Table [1](#SM3){ref-type="supplementary-material"}). The second module correlated with dose ("royal blue") was enriched for ESR1 and ESR2 genes (Table [6](#T6){ref-type="table"}), however, neither ESR1 nor ESR2 was present in the module (or any module correlated positively or negatively with dose) and instead the main hub was TOP2A (Topoisomerase IIA). The module had a weak over-representation of genes involved in development (*p*-value 0.00416) and cytoskeleton organization (*p*-value 0.0155) (Supplementary Table [1](#SM3){ref-type="supplementary-material"}). The other module enriched for ESR1 and ESR2 genes ("dark gray") was also annotated to "response to unfolded protein" (*p*-value of 9.52E-05) (Supplementary Table [1](#SM3){ref-type="supplementary-material"}).

###### 

BPA modules associated with dose.

  Module         Correlation    *p*-Value
  -------------- -------------- -----------
  Lightcyan 1    0.725175961    6.17E-15
  Royal Blue     0.423995959    5.84E-05
  Dark Gray      0.390795349    2.38E-04
  Light Yellow   0.383058412    3.23E-04
  Ivory          -0.372076037   4.92E-04
  Light Cyan     -0.291083662   7.23E-03
  Green          -0.280875808   9.65E-03
  Gray60         -0.279474408   1.00E-02

All BPA modules correlated with estrogen dose-response curve with a p-value less than 0.01.

###### 

Enriched transcription factors in BPA modules.

  Module       TF       Adjusted *p*-value
  ------------ -------- --------------------
  Dark Gray    ESR1     1.32E-16
               ESR2     2.74E-08
               ZNF217   0.000002163
               GATA3    0.00001401
  Green        ZNF217   1.59E-11
               RACK7    0.00006931
               ESR2     0.0001032
               GATA3    0.0002586
               TFAP2C   0.00055
               ESR1     0.002135
               PADI4    0.002604
               FOXM1    0.003341
  Light Cyan   TFAP2C   0.002078
               GATA3    0.002583
  Royal Blue   ZNF217   5.24E-08
               ESR2     7.76E-07
               ESR1     0.000005588
               ARNT     0.00005395
               AHR      0.0002705
               GATA3    0.002178

All statistically significant modules correlated with dose, with enriched transcription factors. Modules that did not have TFs with adjusted p-value ≤ 0.01 were excluded (LightCyan1, Ivory, Light Yellow, Plum, Gray60).

### Low-Dose BPA Network Shows No Enrichment of ESR1 or ESR2 Genes

It has been speculated that BPA at low doses has fundamentally different effects than at high doses; in the original study of the dataset, the authors detected a weak, but distinct, transcriptional activity peak at low doses. Therefore, we restricted the BPA network to doses below 12.5 μM (leaving a highest dose of 6.25 μM, and most of the dose-response curve in the nanomolar/picomolar range) and calculated a network specific for this lower dose range. Despite the smaller sample size, the network still produced several modules that were significantly correlated with dose (Supplementary Figure [1C](#SM1){ref-type="supplementary-material"} and Table [7](#T7){ref-type="table"}). This low-dose BPA network shows consistent transcription factors (ZNF217, TFAP2C, RACK7/ZMYND8, and PADI4) with the larger BPA network as well as the estrogen network, but no modules were enriched for genes with ESR1 or ESR2 with a *p*-value cut-off of \< 0.01 (Table [8](#T8){ref-type="table"}).

###### 

Low-dose BPA modules associated with dose.

  Module          Correlation   *p*-value
  --------------- ------------- -----------
  Turquoise       0.71054       5.21E-06
  Dark Green      0.66763       2.99E-05
  Dark Red        0.54873       1.15E-03
  Light Yellow    0.47024       6.61E-03
  Brown           0.45995       8.08E-03
  Salmon          0.44326       1.11E-02
  Grey60          -0.4753       5.98E-03
  Blue            -0.539        1.46E-03
  Yellow          -0.5535       1.02E-03
  Black           -0.6395       8.13E-05
  Midnight Blue   -0.736        1.58E-06

All low-dose BPA modules correlated with estrogen dose-response curve with a p-value less than 0.01.

###### 

Enriched transcription factors in low-dose BPA modules.

  Module      TF       Adjusted *p*-value
  ----------- -------- --------------------
  Black       RACK7    1.78E-07
              TFAP2C   0.00001339
              RUNX1    0.00004104
  Blue        ELK1     0.00000437
              ZNF217   6.14E-07
              PADI4    0.000007639
              FOXM1    9.66E-08
              HIF1A    0.005915
              AHR      0.00208
              E2F1     0.002221
              ARNT     0.005915
              RUNX1    0.008124
              GATA3    0.008124
  Brown       E2F1     0.002459
              PADI4    0.006908
  Turquoise   ZNF217   0.00000179
              RACK7    0.00001912
              GATA3    0.00002574
              PADI4    0.0001018
              FOXM1    0.0001703
              RUNX1    0.0004958
              E2F1     0.001544
  Yellow      E2F1     6.34E-18
              PADI4    0.003362
              RACK7    0.00334
              FOXM1    0.009047

All statistically significant modules correlated with dose, with enriched transcription factors. Modules that did not have TFs with adjusted p-value ≤ 0.01 were excluded (Light Yellow, Salmon, Gray60, Dark Green, Midnight Blue, Dark Red).

The module with the highest correlation with dose ("turquoise") was comparatively dense for predicted protein-protein interactions (*p*-value of \< 1.0e-16, average node degree 10.3) as well as genes related to cellular macromolecule metabolic process and poly(A) RNA binding (*p*-value of 1.58E-16 and 2.17eE-18, respectively) (Supplementary Table [1](#SM3){ref-type="supplementary-material"}) in contradistinction to the estrogen network, where the dominant module was enriched overwhelmingly with cell-cycle genes. Moreover, the module included both ZNF217 and TFAP2C, but neither ESR1 nor ESR2 were in the module, much less hubs. The second module correlated with dose ("Dark Green") showed no enrichment for transcription factors, although it was enriched for protein--protein interactions and the molecular function "enzyme binding"; the third module ("dark red"), also strongly correlated with dose, showed no enrichment for transcription factors or protein--protein interactions, though it was weakly enriched for the KEGG pathway Insulin Signaling (*p*-value 0.0028); this module may simply be an artifact, reflect diffuse alterations that are difficult to detect, or an unknown regulatory mechanism. An additional fairly large module correlated with dose ("brown") was enriched for both E2F1 and PADI4, strongly enriched for protein-protein interactions (*p*-value \< 1.0E-16, average node degree 6.56) and as well as cellular metabolic process (*p*-value 1.32E-10) and poly(A) RNA binding (*p*-value 2.5E-16) (Supplementary Table [1](#SM3){ref-type="supplementary-material"}); but, also in contrast to the estrogen network, was not enriched for cell-cycle genes.

ZNF217 has previously been shown by our work ([@B29]) and others ([@B11]) to be a critical component of estrogen signaling and an important prognostic factor for breast cancer ([@B41]). Similarly, TFAP2C is known to modulate ESR1 and GPR30 expression, and attenuate the expression of several estrogen-targeted genes ([@B43]). Given the presence of both ZNF217 and TFAP2C in the network as well as the strong enrichment genes targeted by these transcription factors, this suggests that these genes are indeed central to mediating BPAs phenotypic effects; however, our study shows little evidence that they are in exerting their effect in tandem with ESR1 or ESR2.

Moreover, both ZNF217 and TFAP2C were shown independently to be altered by bisphenol A in a rat seminiferous tubule culture model ([@B2]). The same study also showed alterations (albeit subtle) in PADI4 and RACK7 (official gene symbol: ZYMND8) mRNA as well as RACK7/ZMYND8 methylation; neither of these genes were in our dataset so their role in observed changes remains speculative. However, RACK7/ZYMND8 binds a large set of active enhancers, including almost all "super-enhancers," and is therefore expected to have sweeping transcriptional effects ([@B35]). Although little is known about its role in breast cancer, it is thought to inhibit HIF-dependent breast-cancer progression ([@B7]). PADI4 is known to be implicated in cancer and is thought to respond to estrogen-simulation in MCF-7 cells through both genomic and non-genomic mechanisms ([@B10]). In breast cancer specifically, it is implicated in the ELK1/C-Fos pathway ([@B45]). Moreover, BPA was shown to increase protein levels of PADI4 via a reactive oxygen species mechanism in neuroblastoma cells ([@B28]).

Low-Dose BPA Network Had Unique Transcription Factors Not Present in the Estrogen Dataset
-----------------------------------------------------------------------------------------

To further delineate possible transcription factors unique to BPA signaling compared to estrogen, we examined the list of genes in all modules statistically significantly associated with the low-dose BPA network that were not present in the estrogen network, a total of 1,901 genes. Analyzed against the CHEA dataset, the genes were again enriched for RACK7/ZMYND8, in addition to ELK1 and HIF1A (Supplementary Table [2](#SM4){ref-type="supplementary-material"}). In order to expand our search for transcription factors that may not have been studied in MCF-7 cells in the CHEA data set, we also analyzed the list of genes for enrichment against the ARCHS4 database ([@B18]), which correlates transcription factor expression against gene expression in a combined database of over 20,000 RNASeq samples. Of the top 50 transcription factors identified as significantly correlated with the gene list, 18 were also present in the low-dose BPA network (Table [9](#T9){ref-type="table"}). The highest-ranking transcription factor, FIZ1, is zinc-finger protein with a largely unknown biological role ([@B42]) - it has a relatively poor literature base, with only 8 citations in PubMed. However, FIZ1 expression in breast cancer is statistically associated with progesterone receptor status, estrogen receptor status, and sample subtype, and it undergoes extensive CpG-island methylation (Supplementary Figure [2](#SM2){ref-type="supplementary-material"}), and it is therefore an intriguing candidate for further study. The second highest-ranking transcription factor, SREBF1 is comparatively better characterized: it is known to be central to lipid homeostasis, regulating the LDL receptor gene as well as related fatty acid and cholesterol synthesis genes. Furthermore, SREBF1 mRNA was identified as upregulated in adipocytes by BPA ([@B3]). Neither SREBF1 nor FIZ1 were present in the estrogen dataset, and SREBF1- and FIZ1-correlated genes were not enriched in the subset of estrogen-only genes. It is therefore plausible that these two transcription factors are more central to BPAs effects than estrogen, however, because enrichment for transcription factors motifs/regulated genes in any gene list often produce false-positives, understanding their role would require further study.

###### 

Transcription factors unique to low-dose BPA network.

  ------------------------------
  ![](fgene-09-00508-t009.jpg)
  ------------------------------

Genes unique to low-dose BPA compared to estrogen were analyzed against the ARCHS4 for potential transcription factor enrichment; all the transcription factors also present in the dataset were identified in yellow.

Discussion
==========

Estrogen signaling is unique amongst nuclear receptors in that substantial number of the genes altered by estrogen do not have canonical estrogen response elements ([@B26]) -- estrogen signaling takes place within a transcriptomic and epigenomic context that markedly influences receptor activation. Our examination of the estrogen dose response curve network both confirmed several of the transcription factors identified previously, such as E2F1, ZNF217 and TFAP2C, as well as suggested other transcriptional factors such as PADI4 and RACK7/ZYMND8 that may impact estrogen signaling.

Our study is consistent with other findings that the assumption that BPA works exclusively or even predominantly on canonical ESR1 or ESR2 gene regulation may be misleading or an oversimplification ([@B9]; [@B23]). To be sure, one can find gene patterns similar to those found in estrogen-induced cells, but the leap from that observation to the presumption that such changes are estrogen-mediated may not be warranted. While this study cannot determine conclusively the ultimate chain of events that leads from the molecular initiating event to the phenotypic consequences, it does suggest some hypotheses that are more probable. The lack of overlap in the consensus network indicates that despite similarity of genes, there is minimal conservation of network topology, and the one conserved module was not enriched for ESR1 or ESR2 genes. In networks drawn separately from dose-response curves for estrogen and BPA, the substantial differences in network topology, the absence of ESR1 as a hub gene in the BPA network, and the differences in biological function of the modules suggest that even at high-doses, BPAs effects are fundamentally different than estradiol. The lack of estrogen receptor target genes in the low dose BPA network in the presence of a clear signature of other transcription factors suggests that at low doses BPA's effects are driven by mechanisms other than direct estrogen receptor activation. Additionally, regardless of molecular initiating event, assessing BPAs dose-response by looking at estrogen gene-signatures may miss interesting and important biology, such as the likely role of SREBF1. Furthermore, our study is consistent with other findings that BPA's effects are subtle and phenotypic changes likely reflect modest effects at multiple different points ([@B30]) and that analyzing the effects of low-dose BPA can reveal effects that are obscured at higher doses ([@B36]). This does not necessarily lead to a "non-monotonic" dose response curve-- this could be due to technical reasons, or higher-doses could cause non-specific changes that are the result of cellular stress, as evidenced by the identification of modules associated with unfolded protein response. It does, however, point to a need to consider the doses chosen for an *in vitro* study carefully and to not presume linear effects.

This study is certainly not a definitive study of BPA molecular mechanisms: our conclusions cannot confidently be extrapolated to other tissue types, as BPA may have tissue specific effects; MCF-7 cells are prone to artifacts ([@B16]); and our study did not focus on epigenetic mechanisms which are speculated as significantly underpinning much of the observed adverse events seen with BPA exposure, especially at a low dose ([@B37]). While using the CHEA dataset and restricting candidate transcription factors to those observed in MCF-7 cells eliminates many of the false-positives intrinsic to such approaches, it also limits findings to those transcription factors that have been studied, and this may miss some important biology. Extending our analysis with the ARCHS4 database added interesting candidates, but all correlation-based approaches must be treated with caution and viewed as "hypothesis-generating," and all exploratory data analysis techniques such as WGCNA require further targeted studies to confirm suggested molecular networks.

Nonetheless, our study does indicate that transcriptomics, especially given a high-dimensional dataset and the use of non-inferential methods, can likely aid toxicologists in having a better understanding of probable molecular targets as well as the complexity of perturbed networks - clearly, understanding BPAs effects will require a systems level approach ([@B13]) as well as better characterization of genes that are not as yet confidently mapped as to biological function. More generally speaking, this points to the pitfall of trying to design "greener" substitutes ([@B24]; [@B100]) in the absence of a clear, comprehensive understanding of molecular mechanism.
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Methylation pattern for FIZ1 in BRCA TCGA data set.
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Protein-protein interaction and enrichment from STRING database.
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Transcription factors for genes present only in low-dose BPA network.
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